In this episode, Martin discusses why he believes Nidec is positioned to benefit from the continued expansion of AI infrastructure and data centers. He also explains his decision to reduce exposure to technology stocks in favor of AbbVie, examining the pharmaceutical company’s valuation and growth outlook, before analyzing Lam Research (LRCX) and the opportunities and risks surrounding semiconductor equipment demand and the broader chip cycle.
Podden och tillhörande omslagsbild på den här sidan tillhör
Urban Tapes. Innehållet i podden är skapat av Urban Tapes och inte av,
eller tillsammans med, Poddtoppen.
